Apatinib plus etoposide as second-or higher-line treatment in recurrent or metastatic triple-negative breast cancer: A single-arm, open label, prospective, phase II clinical trial.
Journal of Clinical Oncology（2022）
关键词
breast cancer,apatinib,clinical trial,higher-line,triple-negative,single-arm
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要